DAB2
DAB2장애 호몰로그 2는 DAB2 [5][6]유전자에 의해 인간에게 암호화되는 단백질이다.
기능.
DAB2 mRNA는 정상적인 난소 상피 세포에서 발현되지만, 난소암 세포주에서는 하향 조절되거나 존재하지 않는다.770-아미노산 예측 단백질은 추정 마이트겐 응답 인단백질인 마우스 p96 단백질과 전체 83%의 동일성을 가지고 있으며, 호몰로지는 포스포티로신 상호작용 도메인에 해당하는 영역에서 단백질의 아미노 말단 말단에서 가장 강하다.DAB2의 하향 조절은 난소 발암에 중요한 역할을 할 수 있다.이 유전자는 처음에 DOC2(난소암에서 다르게 발현된 경우)로 명명되었으며 DOC2A 및 DOC2B 유전자(이중 C2 유사 도메인인 경우 알파 및 베타)[7]와 구별된다.
상호 작용
DAB2는 다음 부품과 상호 작용하는 것으로 나타났습니다.
레퍼런스
- ^ a b c GRCh38: 앙상블 릴리즈 89: ENSG00000153071 - 앙상블, 2017년 5월
- ^ a b c GRCm38: 앙상블 릴리즈 89: ENSMUSG000022150 - 앙상블, 2017년 5월
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ Albertsen HM, Smith SA, Melis R, Williams B, Holik P, Stevens J, White R (January 1997). "Sequence, genomic structure, and chromosomal assignment of human DOC-2". Genomics. 33 (2): 207–13. doi:10.1006/geno.1996.0185. PMID 8660969.
- ^ Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS (June 1998). "DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer". Oncogene. 16 (18): 2381–7. doi:10.1038/sj.onc.1201769. PMID 9620555.
- ^ "Entrez Gene: DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)".
- ^ a b Zhou J, Scholes J, Hsieh JT (February 2003). "Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer". J. Biol. Chem. 278 (9): 6936–41. doi:10.1074/jbc.M210628200. PMID 12473651.
- ^ a b He J, Xu J, Xu XX, Hall RA (July 2003). "Cell cycle-dependent phosphorylation of Disabled-2 by cdc2". Oncogene. 22 (29): 4524–30. doi:10.1038/sj.onc.1206767. PMID 12881709.
- ^ Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT (April 2002). "The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2". J. Biol. Chem. 277 (15): 12622–31. doi:10.1074/jbc.M110568200. PMID 11812785.
- ^ a b Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH (June 2003). "Regulation of the Wnt signaling pathway by disabled-2 (Dab2)". EMBO J. 22 (12): 3084–94. doi:10.1093/emboj/cdg286. PMC 162138. PMID 12805222.
- ^ Oleinikov AV, Zhao J, Makker SP (May 2000). "Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin". Biochem. J. 347 Pt 3 (3): 613–21. doi:10.1042/0264-6021:3470613. PMC 1220996. PMID 10769163.
- ^ Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F (May 2002). "Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton". Traffic. 3 (5): 331–41. doi:10.1034/j.1600-0854.2002.30503.x. PMID 11967127. S2CID 25079713.
- ^ Inoue A, Sato O, Homma K, Ikebe M (March 2002). "DOC-2/DAB2 is the binding partner of myosin VI". Biochem. Biophys. Res. Commun. 292 (2): 300–7. doi:10.1006/bbrc.2002.6636. PMID 11906161.
- ^ a b Hocevar BA, Smine A, Xu XX, Howe PH (June 2001). "The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway". EMBO J. 20 (11): 2789–801. doi:10.1093/emboj/20.11.2789. PMC 125498. PMID 11387212.
추가 정보
- Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS (1994). "Molecular cloning of differentially expressed genes in human epithelial ovarian cancer". Gynecol. Oncol. 52 (2): 247–52. doi:10.1006/gyno.1994.1040. PMID 8314147.
- Bonaldo MF, Lennon G, Soares MB (1996). "Normalization and subtraction: two approaches to facilitate gene discovery". Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548.
- Xu XX, Yi T, Tang B, Lambeth JD (1998). "Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2". Oncogene. 16 (12): 1561–9. doi:10.1038/sj.onc.1201678. PMID 9569023.
- Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX (1999). "Disabled-2 inactivation is an early step in ovarian tumorigenicity". Oncogene. 18 (20): 3104–13. doi:10.1038/sj.onc.1202649. PMID 10340382.
- Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT (1999). "The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer". J. Biol. Chem. 274 (45): 31981–6. doi:10.1074/jbc.274.45.31981. PMID 10542228.
- Oleinikov AV, Zhao J, Makker SP (2000). "Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin". Biochem. J. 347 Pt 3 (3): 613–21. doi:10.1042/0264-6021:3470613. PMC 1220996. PMID 10769163.
- Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX (2000). "Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells". Oncogene. 19 (42): 4847–54. doi:10.1038/sj.onc.1203853. PMID 11039902.
- Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX (2000). "Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2)". Genomics. 70 (3): 381–6. doi:10.1006/geno.2000.6383. PMID 11161789.
- Morris SM, Cooper JA (2001). "Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2". Traffic. 2 (2): 111–23. doi:10.1034/j.1600-0854.2001.020206.x. PMID 11247302. S2CID 33186168.
- Zhou J, Hsieh JT (2001). "The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2". J. Biol. Chem. 276 (30): 27793–8. doi:10.1074/jbc.M102803200. PMID 11371563.
- Hocevar BA, Smine A, Xu XX, Howe PH (2001). "The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway". EMBO J. 20 (11): 2789–801. doi:10.1093/emboj/20.11.2789. PMC 125498. PMID 11387212.
- Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT (2002). "The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2". J. Biol. Chem. 277 (15): 12622–31. doi:10.1074/jbc.M110568200. PMID 11812785.
- Inoue A, Sato O, Homma K, Ikebe M (2002). "DOC-2/DAB2 is the binding partner of myosin VI". Biochem. Biophys. Res. Commun. 292 (2): 300–7. doi:10.1006/bbrc.2002.6636. PMID 11906161.
- Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, Traub LM (2002). "Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor". EMBO J. 21 (18): 4915–26. doi:10.1093/emboj/cdf487. PMC 126284. PMID 12234931.
- Morris SM, Tallquist MD, Rock CO, Cooper JA (2002). "Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport". EMBO J. 21 (7): 1555–64. doi:10.1093/emboj/21.7.1555. PMC 125955. PMID 11927540.
- Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F (2002). "Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton". Traffic. 3 (5): 331–41. doi:10.1034/j.1600-0854.2002.30503.x. PMID 11967127. S2CID 25079713.
- Zhou J, Scholes J, Hsieh JT (2003). "Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer". J. Biol. Chem. 278 (9): 6936–41. doi:10.1074/jbc.M210628200. PMID 12473651.
- Calderwood DA, Fujioka Y, de Pereda JM, García-Alvarez B, Nakamoto T, Margolis B, McGlade CJ, Liddington RC, Ginsberg MH (2003). "Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling". Proc. Natl. Acad. Sci. U.S.A. 100 (5): 2272–7. doi:10.1073/pnas.262791999. PMC 151330. PMID 12606711.